Seven-month kinetics of SARS-CoV-2 antibodies and protective role of pre-existing antibodies to seasonal human coronaviruses on COVID-19

Natalia Ortega^{1a}, Marta Ribes^{1a}, Marta Vidal¹, Rocío Rubio¹, Ruth Aguilar¹, Sarah Williams¹, Diana Barrios¹, Selena Alonso¹, Pablo Hernández-Luis^{2,3}, Robert A. Mitchell¹, Chenjerai Jairoce^{1,4}, Angeline Cruz¹, Alfons Jimenez^{1,5}, Rebeca Santano¹, Susana Méndez¹, Montserrat Lamoglia^{1,6}, Neus Rosell¹, Anna Lluçà^{1,7}, Laura Puyol¹, Jordi Chi¹, Natalia Rodrigo Melero⁸, Daniel Parras², Pau Serra², Edwards Pradenas⁹, Benjamin Trinité⁹, Julià Blanco^{9,10}, Alfredo Mayor^{1,4,5}, Sonia Barroso¹¹, Pilar Varela¹¹, Anna Vilella^{1,5}, Antoni Trilla^{1,5,12}, Pere Santamaria^{7,13,14}, Carlo Carolis⁸, Marta Tortajada¹¹, Luis Izquierdo¹, Ana Angulo^{2,3}, Pablo Engel^{2,3}, Alberto L. García-Basteiro^{1,4,15}, Gemma Moncunill^{1*}, Carlota Dobaño^{1,5*}

Affiliations

¹ ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain

² Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain

³ Immunology Unit, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain

⁴ Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique

⁵ Spanish Consortium for Research in Epidemiology and Public Health, Madrid, Spain

⁶ School of Health Sciences TecnoCampus Universitat Pompeu Fabra, Mataró, Spain

⁷ Department of Preventive Medicine and Epidemiology, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain

⁸ Biomolecular screening and Protein Technologies Unit, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.

⁹ IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916, Badalona, Catalonia, Spain

¹⁰ University of Vic–Central University of Catalonia (UVic-UCC), 08500, Vic, Catalonia, Spain

¹¹ Occupational Health Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain

¹² Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain

¹³ Julia McFarlane Diabetes Research Centre, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.

¹⁴ Department of Microbiology, Immunology and Infectious Diseases, Snyder Institute for Chronic Diseases, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

¹⁵ International Health Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain

^a Shared first authors

* Shared last authors and correspondence:

Carlota Dobaño, carlota.dobano@isglobal.org

Gemma Moncunill, gemma.moncunill@isglobal.org

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

ISGlobal, Carrer Roselló 132, 08036 Barcelona, Spain

Abstract

Unraveling the long-term kinetics of antibodies to SARS-CoV-2 and its determinants, including the impact of pre-existing antibodies to human coronaviruses causing common cold (HCoV), is essential to understand protective immunity to COVID-19 and devise effective surveillance strategies. IgM, IgA and IgG levels against six SARS-CoV-2 antigens and the nucleocapsid antigen of the four HCoV (229E, NL63, OC43 and HKU1) were quantified by Luminex, and antibody neutralization capacity was assessed by flow cytometry, in a cohort of health care workers followed-up for 6 months (N = 578). Seroprevalence increased over time from 13.5% (month 0) and 15.6% (month 1) to 16.4% (month 6). Levels of antibodies, including those with neutralizing capacity, were stable over time, except IgG to nucleocapsid antigen and IgM levels that waned. After the peak response, anti-spike antibody levels increased from ~150 days post-symptom onset in all individuals (73% for IgG), in the absence of any evidence of re-exposure. Pre-existing antibodies to alpha-HCoV were lower in individuals who subsequently seroconverted for SARS-CoV-2. IgG and IgA to HCoV were significantly higher in asymptomatic than symptomatic seropositive individuals. Thus, pre-existing cross-reactive HCoV antibodies could have a protective effect against SARS-CoV-2 infection and COVID-19 disease.

Introduction

Coronavirus disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has already caused a loss of 3.2 M lives globally¹. Since its emergence, a key priority has been the understanding of the kinetics and protective role of the immune response in the population, to assess the degree of exposure in serosurveys and to understand immunity to the virus. This knowledge guides vaccine development, selection of donors for hyperimmune serum-transfusion therapies, and combining antigens with the highest immunogenic and neutralizing capacity to improve surveillance interventions. Longitudinal studies assessing SARS-CoV-2 antibody kinetics have found that IgA and IgM peak between week 3 and 4 post symptoms onset (PSO) and wane thereafter, with IgA persisting longer than IgM²⁻⁷. IgA and IgM seroreversion was estimated between days 71 and 49, respectively⁸, but IgA has also been found to remain detectable 6 months post infection and to be less affected by the decay than IgM^{9,10}. Several studies have observed relatively stable levels of IgG to the spike (S) protein after three^{11,6}, four^{12,13} and six to eight months^{2,9,14-16}. However, others reported that IgG only lasted around 3-4 months PSO^{17,18}. Many studies consistently observe that IgG to the nucleocapsid (N) protein, found inside the virus or infected cells, decay faster than IgG to S, being a marker of a more recent infection but less sensitive for assessing population seroprevalence^{2,13-20}. While antibodies targeting N protein are unlikely to directly neutralize SARS-CoV-2, those targeting S, responsible for the interaction with the ACE2 receptor in the host cells, are considered the main neutralizers²¹. Studies up-to-date point that neutralizing antibodies (nAbs) strongly correlate with antibody titers to S^{16,19-22} and also positively correlate with increased disease severity²⁶. Understanding the extent of antibody cross-reactivity with other human coronaviruses (HCoV) is important to elucidate the impact of such pre-existing antibodies on COVID-19 immunity. Four low-pathogenic HCoV causing common cold have circulated among humans for at least 100 years: the alphacoronaviruses 229E and NL63, and the betacoronaviruses OC43 and HKU1. They account for about 10% of all acute respiratory tract infections, and thus, a substantial proportion of the global population is expected to carry antibodies against

them^{27,28}, although their protective immunity might be short-lasting²⁹ Previous studies found some cell-mediated^{30,31} and antibody cross-reactivity of HCoV immune responses with SARS-CoV-2³²⁻³⁴. Regions within N and S antigens with high amino acid homology between SARS-CoV-2 and HCoV are potential targets of cross-reactive antibodies³³⁻³⁶, and could exert cross-protective effects against SARS-CoV-2 infection and/or disease. Prior studies have not found protection against infection, as participants with recent documented infection with an endemic HCoV had similar rates of SARS-CoV-2 acquisition than those without recent HCoV infection³⁷⁻³⁹. Regarding anti-disease protection, COVID-19 patients with a recent HCoV diagnosis had statistically significant lower odds for COVID-19 intensive care unit admission and death³⁹, but other studies did not find any association between confirmed prior history of seasonal HCoVs and COVID-19 severity^{37,38}. Some recent studies have suggested that this pre-existing immunity would not confer cross-protection but, rather, be responsible for an immunological imprinting or ‘original antigenic sin’, a phenomenon well studied for influenza virus infections. This suggests that the immune system privileges recall of existing memory responses -in this case of HCoV-, in detriment of stimulating *de novo* responses -here to SARS-CoV-2- leading to poor outcomes or severe disease^{31,32}. The possibility of antibodies to HCoVs acting as antibody-derived enhancement (ADE) has also been reviewed and the most recent evidence shows no clinical, *in vitro* or animal evidence^{40,41}. Disentangling the role of pre-existing HCoVs antibodies on anti-SARS-CoV-2 responses may have implications in the deployment of potentially effective vaccines, as well as for the interpretation of serological studies.

At the beginning of the pandemic, healthcare workers (HCW) were considered to be at a higher risk of SARS-CoV-2 infection than the general population, although there is now evidence that seroprevalence is similar when using adequate personal protective equipment. We previously observed 9.3% (95% CI, 7.1-12.0) SARS-CoV-2 seroprevalence in a random cohort of 578 HCW from Hospital Clínic in Barcelona (HCB) between March-April 2020⁴², and of 14.9% after a month follow-up⁴, based on the detection of antibodies to one antigen

(receptor binding domain, RBD). IgA, IgM and IgG levels declined after 3 months with antibody decay rates of 0.12, 0.15 and 0.66 respectively⁴. In the present study, we aimed to characterize the antibody kinetics and neutralization capacity between March and October 2020 at four cross-sectional surveys and estimate the seroprevalence in the same cohort of HCW. For this analysis, we measured IgM, IgG and IgA isotypes against an expanded panel of six SARS-CoV-2 antigens and tested cross-reactivity with the N antigen of the four endemic HCoV-229E, HKU1, NL63 and OC43 to assess its potential impact on COVID-19 protection.

Results

Seroprevalence, seroconversions and seroreversions

From the initial cohort, 507 individuals participated in a fourth visit (M6) six months after baseline (12.3% lost to follow-up). Mean age was 42.7 (SD: 11.2) and 72% were female. Full demographic characteristics at baseline (M0), one (M1) and three (M3) month follow up visits were as described^{4,42} (**Supplementary Table 1**).

Samples collected at M0, M1 and M3 were re-tested with a wider panel of antigens along with M6 samples. The seroprevalence for either IgM and/or IgG and/or IgA was 13.5% at M0, 15.6% at M1 and 16.4% at M6 (**Supplementary Table 2**). Newly detected SARS-CoV-2 infections increased by 22, 9 by rRT-PCR and 13 by serology, at M6 compared to visit M1. When considering rRT-PCR and serology data, 84 out of 578 participants (14.5%, 95% CI 11.8-17.7%) had evidence of infection at M0 by serology or rRT-PCR, 91/566 (16.1%, 95% CI 13.1-19.4%) at M1 and 91/507 (17.9%, 95% CI 14.7-21.6%) at M6. The cumulative prevalence of infection was 16.8% (95% CI 13.8-20.1%) and 19.6% (95% CI 16.4-23.0%) at M1 and M6, respectively. Unlike seropositive proportions, we had a relatively stable number of undetermined results over time, 48 (8.3%), 52 (9.1%) and 37 (7.3%) participants at baseline, M1 and M6, respectively. Sixty-seven out of the 119 participants (56.3%) with any evidence of infection had a positive rRT-PCR (**Supplementary Table 2**).

At visits M1 and M3, we mainly observed seroreversions of seropositive individuals at M0 for IgA and IgM to all antigens (30% and 24.5%, respectively). Hardly any participant seroreverted from M3 to M6 (**Supplementary Table 2**). Overall, there were 9 participants who were seronegative and previously had a positive rRT-PCR, 32 to 197 days prior to sample draw. Three of these HCWs were asymptomatic. Having reported COVID-19-compatible symptoms at any visit was associated with experiencing a SARS-CoV-2 infection with an OR of 463 (95% CI, 122 -3157) in the univariable analysis. Physicians and psychologists had 50% lower odds of infection (OR 0.49, 95% CI 0.27-0.85) than nurses and other auxiliary health professionals (**Supplementary Table 3**). Age, sex and other variables were not found to be associated with SARS-CoV-2 infection. Sixty-nine percent of the infections were symptomatic and a single participant required hospitalization in our cohort.

Kinetics of SARS-CoV-2 antibodies up to 7.7 months PSO

Levels of SARS-CoV-2 antigen specific isotypes (IgM, IgA, IgG) were plotted against time with up to four observations with a maximum 7.7 months PSO, in a total of 235 samples from 76 symptomatic participants (**Figure 1**). Kinetic curves were very similar when plotted against days since positive rRT-PCR in participants who were asymptomatic or symptomatic (**Supplementary Figure 1**). IgA or IgM peaked within the first month PSO, while IgG peaked around day 50 PSO. SARS-CoV-2 IgG levels were generally steady for S antigens (S, S1, S2 and RBD) and for IgA up to 230 days PSO (71% and 69% of the participants remained seropositive six months PSO, respectively), and waned at a clearly slower rate than IgM (34% of the participants remained seropositive) and IgG to N-related antigens (26% of the participants remained seropositive). Antibody levels were observed to increase from ~150 days PSO onwards (**Figure 1**). To further explore this, we grouped participants based on their antibody levels at M6 compared to the previous visit (M1 or M3). We only considered participants who had already shown a decrease in antibodies after the peak response. We therefore calculated an “antibody

increase index" between both visits for each antigen-isotype combination and labelled the individuals as "decayers" when the ratio of antibody levels between both visits was <1 , and as "sustainers/increasers" when the ratio was ≥ 1 , in line with the methodology by Chen et al.¹⁷. Increased levels were observed in all antigen-isotype combinations (**Figure 1**). Most sustainers/increasers had a boost for more than one antigen-isotype pair, as assessed by a Venn diagram (**Supplementary Figure 2**). Levels at seroconversion visit were higher in decayers than sustainers/increasers, being statistically significant for N IgG, S2 IgG and S1 IgM (**Supplementary Figure 3a**). There was no association of the antibody increase index or being a sustainer/increaser or a decayer with age. We observed a trend towards having a higher antibody increase index, mainly for IgG, in participants who reported current or past symptoms at M6 since last visit, several months after COVID-19 disease recovery (**Supplementary Figure 3b**). Of note, none of these individuals reported new infections and we did not find any association between having reported a contact with a COVID-19 case at M6 and the antibody increase index (data not shown). We also identified a trend towards higher antibody increase index in participants with shorter duration of symptoms (<10 days) compared to those who had symptoms for >10 days (**Supplementary Figure 3c**). We explored all the variables in univariable and multivariable logistic regression models and none were robustly associated with being a sustainer/increaser or a decayer (data not shown).

Kinetics of neutralizing antibodies

Plasma neutralizing capacity measured as RBD-ACE2-binding inhibition generally increased between the day of onset of symptoms until day 80 and remained stable thereafter up to 250 days PSO (**Figure 2**). We correlated the antibody neutralizing capacity and levels at the different study visits. At the first cross-sectional visit (M0, mean days PSO=20) levels of all three Ig isotypes against RBD and S antigens positively correlated with neutralization capacity ($r_s=0.19-0.32$, $p<0.05$), while the correlation between antibody levels against N and RBD-ACE2 neutralization did not reach statistical significance (**Figure 3a**). At the fourth

cross-sectional visit (M6, mean days PSO=200), IgM levels to any antigen did not correlate with neutralization percentage, whilst IgG and IgA levels against all six antigens showed moderate to strong correlations ($r_s=0.24-0.76$, $p<0.05$), with higher correlations for S antigens (**Figure 3b**). We performed a PCA for all antigen-isotype pairs (**Supplementary Figure 4**) and the first 5 components, explaining 75.12% of the variance were included as predictors in a model with neutralizing capacity as an outcome ($p<0.05$, adjusted R^2 0.575). Component 1 and 5 were significantly associated with neutralizing capacity (**Supplementary Table 4**). In these components, S and S1 IgG, and S2 IgM, contributed to an increase in the neutralization activity, whilst N C-terminal IgG negatively influenced it ($p<0.001$). We observed that antibodies to S antigens were highly contributing to the prediction of the neutralization percentage (component 1, longer vectors). We did not find any significant difference in neutralizing capacity between sustainers/increasers and decayers. The neutralizing capacity was also not associated with the antibody increase index, except for IgM increase index that inversely correlated with the neutralization percentage at M0 and after six months PSO (**Supplementary Figure 5**).

Cross-reactivities of SARS-CoV-2 with endemic HCoV

Pre-pandemic plasma samples had some antibody reactivity against SARS-CoV-2 antigens, particularly against N protein, and levels of antibodies against N from SARS-CoV-2 positively correlated with antibodies to HCoV N antigens (to a lesser extent for IgM), indicating cross-reactivity between them (**Supplementary Figure 6**). The amino acid pairwise similarities and identities of full-length SARS-CoV-2 N protein and seasonal HCoVs are 36% and 26.4% to 229E, 39.1% and 27% to NL63, 48.1% and 35.7% to OC43 and 47% and 35.2% to HKU1³⁶. Therefore, we analyzed the antibody levels against HCoV N antigens prior and after SARS-CoV-2 infection in the 33 participants who seroconverted during the study period. While some participants showed stable anti-HCoV N antibody levels, a general upward trend was observed. IgG to 229E significantly increased after SARS-CoV-2 seroconversion.

Considering that not all seroconverters had an increase in levels supports a back-boost of N HCoV beyond cross-reactivity (**Supplementary Figure 7**).

We investigated whether having higher baseline anti-HCoV N antibody levels could be protective against SARS-CoV-2 infection. Overall, we observed a consistent trend towards higher baseline IgG levels to alpha-HCoV 229 (p=0.06) and NL63 (p=0.15) in participants who did not seroconvert compared to seroconverters, although these differences did not reach statistical significance (**Figure 4a**). We assessed whether having higher anti-HCoV N antibody levels prior to infection could confer protection against COVID-19 symptoms in participants who seroconverted during the study period. Although statistical significance was only reached for IgA against OC43, we observed a common trend towards higher levels of anti-HCoV N IgA and IgG in asymptomatic than symptomatic SARS-CoV-2 seropositive participants (**Figure 4b**). Consistently, levels of all three isotypes against alpha HCoVs and of IgA to OC43 experienced a higher fold-increase after SARS-CoV-2 infection in asymptomatic than symptomatic seroconverters (p<0.05) (**Figure 4c**), suggesting that a back boost -beyond cross-reactivity- in anti-HCoV antibody levels could confer disease-protective immunity. In line with this finding, seropositive asymptomatic participants had significantly higher IgG levels against all four HCoVs than symptomatic participants in the first visit after SARS-CoV-2 positivity (**Figure 4d**). In contrast, anti-SARS-CoV-2 N antibody levels were higher in symptomatic seropositive participants (p<0.05) (**Figure 4e**).

Finally, we tested whether baseline anti-HCoV antibody levels impacted *de novo* production of antibodies to SARS-CoV-2. To test this hypothesis we correlated the increase in anti-N SARS-CoV-2 antibody levels from baseline to seroconversion for the three isotypes against the anti-N HCoVs antibody levels at baseline (adding up levels of isotypes). Overall, we observed a statistically significant inverse relationship between anti-HCoV IgG and IgA baseline levels and the increase of SARS-CoV-2 antibodies ($r_s = -0.35$, p<0.05; $r_s = -0.18$, p<0.05; respectively). This suggests that pre-existing antibodies against the four HCoV N induced a lighter *de novo* production of antibodies against SARS-CoV-2 N (**Supplementary Figure 8**).

Discussion

To our knowledge, this is the first longitudinal study to assess the antibody response to such a wide panel of antigens from SARS-CoV-2 and HCoV, up to 7.7 months after infection, and the first to show evidence of COVID-19 protection by pre-existing HCoV antibodies. This is important to track the evolution of the immunity in asymptomatic and mild/moderate cases, particularly in an indispensable population like HCW, and to understand why some people may be less affected by COVID-19. A strength of the present study is the availability of sequential sampling within a random cohort including asymptomatic and symptomatic subjects.

Importantly, we observed a trend towards higher levels of antibodies against HCoVs N proteins at baseline in those participants who did not become infected with SARS-CoV-2, suggesting some level of cross-protection against infection. Moreover, asymptomatic SARS-CoV-2 seropositive participants tended to have higher anti-HCoV N IgA and IgG levels prior to seroconversion than symptomatic participants, suggesting cross-protection against disease. In addition, asymptomatic seropositive participants had significantly higher anti-HCoV N IgG levels after infection than symptomatics, pointing towards a disease-protective back-boost of anti-HCoV antibodies. Combined with the observation that higher baseline anti-HCoV N antibody levels correlated with less *de novo* anti-SARS-CoV-2 N antibody production, we propose a protective effect of previous exposure to HCoVs, which could be the result of a diminished exposure (decreased viral load) due to the suggested protective role of anti-HCoV antibodies. Other studies have reported a lack of anti-disease cross-protection³⁷⁻³⁹; and some studies have associated severe COVID-19 with a back-boosting of antibodies against S2 from betacoronaviruses³², and N and S from OC43³¹. However, these studies included only hospitalized patients, as opposed to our cohort that included mainly asymptomatic and participants with mild/moderate symptoms. HCoV protective immunity against reinfection has been observed to last around 12 months²⁹. Knowing the duration of HCoV protective immunity to reinfection and disease will be key to the understanding of HCoV's role on COVID-19 epidemiology and pathology at population level. We show a

cumulative prevalence of SARS-CoV-2 infection of 19.6% (95% CI 16.4-23.0%) after six months of follow-up (October 2020). The cumulative prevalence around May 2020, corresponding to our second visit (M1), recalculated here with a wider antigen panel, was 16.8% (CI 95% 13.8-20.1%), similar to other studies in Spanish HCW that ranged between 10.5% and 19.9%⁴³⁻⁴⁵. Around 28% of the total infections detected throughout the follow up were newly diagnosed after the first visit (M0), which would reveal that infections in the hospital setting mostly happened within the first pandemic wave. No re-infections were reported in our cohort and this could be related to the induction and maintenance of robust neutralizing antibodies along the study period, in contrast with another study in a cohort of 173 primary HCW in which 4 reinfections were reported⁴⁶. Surprisingly, only 56% of participants with evidence of infection by serology had a positive rRT-PCR, highlighting that almost half of the infections went under-detected, mainly during the baseline visit (only 49% had a previous positive rRT-PCR) and going up to 73% of rRT-PCR detection rate in the following visits. We observed a high seroreversion rate for IgA and IgM at visits M1 and M3, decreasing at visit M6. This finding reinforces the rapid decay below the seropositivity threshold of these two isotypes compared to IgG, for which only 9 participants seroreverted between M1 and M6 visits. Although some reports have pointed to a higher antibody decay in HCW with mild symptoms⁴⁷, our results show that IgG levels are maintained up to 7.7 months PSO, in line with other studies^{2,9,14-16}. Interestingly, IgA levels were maintained in those individuals who did not serorevert during the first 3 months PSO. Furthermore, IgG to N C-terminal rapidly decreased below the positivity threshold, as seen in other studies^{2,13-20}. However, the vast majority of participants with a previous infection remained seropositive for S-related antigens. This finding is of special relevance because RBD and S IgG antibody levels have been shown to correlate with neutralizing activity and S is the main target of currently deployed COVID-19 vaccines and most products under development. Remarkably, we noticed a pronounced increase in S-related IgG levels from day 150 PSO onwards in 34/46 (73.9%) participants. Previous studies that reached 150 days of follow-up have not highlighted this phenomenon^{6,14,16}, but it was observed in Figueiredo-Campos et

al.⁹. Chen et al. assessed a subset of individuals with stable or increasing antibody levels at day ~100¹⁷. In our study, nearly all increasers showed the boost in levels for more than one antigen-isotype pair, in line with the results observed by Chen et al.¹⁷. We also found a consistent tendency pointing to shorter duration of symptoms in participants with higher increase indices, labeled as quick healers, independently from their age. In contrast with their work, we found statistically significant differences in SARS-CoV-2 antibody levels at seroconversion, with decayers showing higher levels compared to sustainers-increasers for N IgG, S2 IgG and S1 IgM. The increase in antibody levels in recovered participants could be related to a natural boost after a re-exposure, although we do not have any evidence of reinfection, and sustainers/increasers did not report more contacts with positive cases than decayers. A similar late increase in antibody levels has been reported in a study describing immunity to Ebola virus, showing a pattern of decay-stimulation of antibody production in survivors who had been neither re-exposed nor vaccinated, and had been asymptomatic since the infection⁴⁸. The authors argued that the increase in antibodies could be the result of *de novo* antigenic stimulation at immune-privileged sites, that is, the persistence of antigens in specific organs would mimic a re-infection and boost immunity. Interestingly, Gaebler et al. observed antigen persistence in the small intestine and related it with the memory B cell response evolving during the first 6 months after infection, with accumulation of Ig somatic mutations, and production of antibodies with increased neutralizing breadth and potency¹⁰. Strong correlations were found between antibody neutralization capacity and the days PSO, as identified in previous literature^{16,19,20,22}, in accordance with the antibody affinity increase after the maturation of the immune response. Anti-spike antigens contributed to an increase in the antibody neutralization capacity, whilst anti-N C-terminal IgG negatively impacted it. IgM may have a neutralization role early after infection but it may be lost after a few months, consistent with the decay of IgM levels.

Antibodies from sustainers/increasers and decayers had equivalent neutralization capacities, suggesting that the increasing antibody levels observed 150 days PSO are not associated with the quality of the response. Unexpectedly, IgM increase index negatively correlated with

the antibody neutralization capacity at baseline and after six months visits. It would appear that the virus could be more persistent in participants with lower neutralizing capacity and as a result IgM response is successively increased.

The main limitations of this study are that our cohort had few participants with severe disease, and that we only assessed the impact of anti-HCoV N antibodies on SARS-CoV-2 response, while anti-N antibodies are not expected to have neutralizing capacity. However, it is likely that sera with high levels of N HCoV antibodies would also have high levels of antibodies targeting S antigens and B and T cells specific to HCoV, which could explain the potential association with a protective effect. Altogether, further studies will be needed to elucidate the potential role of prior HCoV infections in the spectrum of COVID-19 severity, as well as the temporal relevance of HCoV exposure and the possible impact on vaccine responses.

In conclusion, antibody levels and neutralizing capacity are generally maintained up to 7.7 months, and in a substantial number of individuals antibody levels increase after some months PSO. Further studies are needed to elucidate the mechanisms and nature of these increases and their implications for virus shedding and disease progression. Importantly, previous exposure to HCoVs could have a protective effect against SARS-CoV-2 infection and symptoms development, and may explain in part the differential susceptibility to disease in the population. Additional work focusing on prospective cohorts would allow the assessment of mechanisms and confirm causality in anti-HCoV antibodies on SARS-CoV-2 acquisition, disease progression, immune response maintenance and correlates of protection.

Methods

Study design, population and setting

We measured the levels of antibodies to SARS-CoV-2 antigens in blood samples of 578 randomly selected HCW from HCB followed up at four visits: baseline - hereby termed “M0”- (month 0, March 28th to April 9th 2020, n = 578), “M1” (month 1, April 27th to May 6th 2020, n =

566), “M3” (month 3, July 28th to August 6th 2020) when only participants with previous evidence of infection were invited (n=70), and “M6” (month 6, Sept 29th to Oct 20th 2020, n = 507) (12.3% lost to follow-up). We collected retrospective data on symptoms in order to set the beginning of the disease, and the longest period since symptoms onset was 231 days (7.7 months).

The study population included HCW who delivered care and services directly or indirectly to patients, as described^{4,42}. We collected nasopharyngeal swabs for SARS-CoV-2 rRT-PCR at M0 and M1 and a blood sample for antibody and immunological assessments at all visits. SARS-CoV-2 detection by rRT-PCR followed the CDC-006-00019 CDC/DDID/NCIRD/ Division of Viral Diseases protocol, as previously described^{4,42}. Participants isolated at home due to a COVID-19 diagnosis or on quarantine, were visited at their households for sample and questionnaires collection.

Written informed consent was obtained from all study participants prior to study initiation. The study was approved by the Ethics Committee at HCB (Ref number: HCB/2020/0336). Data for each participant were collected in a standardized electronic questionnaire as described⁴².

Quantification of antibodies to SARS-CoV-2

IgM, IgG and IgA antibodies to the full length SARS-CoV-2 S protein, its subregions S1 and S2, RBD that lies within the S1 region, the N full length protein and its specific C-terminal region, and the full length N protein of the HCoV HKU1, 229E, OC43 and NL63, were measured by Luminex (Supplementary Information) based on a previously described protocol⁵¹. Sequential plasma samples from the same individual were tested together in the same assay plate. Assay positivity cutoffs specific for each isotype and analyte were calculated as 10 to the mean plus 3 standard deviations (SD) of log₁₀-transformed mean fluorescence intensity (MFI) of 129 pre-pandemic controls. Results were defined as undetermined when the MFI levels for a given isotype-analyte were between the positivity threshold and an upper limit at 10 to the mean plus 4.5 SD of the log₁₀-transformed MFIs of pre-pandemic samples, and no other isotype-antigen combination was above the positivity

cutoff and the participant did not have any previous evidence of seropositivity or rRT-PCR positivity.

Neutralizing antibodies

Percentage of inhibition of RBD binding to ACE2 by plasma was analyzed through a flow cytometric-based *in vitro* assay as detailed in the Supplementary Information. This technique stands for its rapidity and efficiency and sets a potential alternative to the more demanding plaque-reduction neutralization assays. Briefly, a murine stable cell line expressing the ACE2 receptor was incubated with RBD-mFc fusion protein, composed of RBD fused to the Fc region of murine IgG1, previously exposed to the different plasma samples at a dilution 1/50. Cells were stained with anti-mouse IgG-PE, washed, and analyzed by flow cytometry using standard procedures. One hundred and one samples were tested alongside 20 positive and 20 negative pre-pandemic controls, in duplicates (**Supplementary Fig 9a**). We cross-validated the neutralization assay with a validated assay⁵². Fifty-five plasma samples were analyzed for pseudovirus neutralization and half maximal dilutions concentrations (ID50) were compared with the results obtained with the flow cytometry. There was a strong correlation ($\rho = 0.9$, $p < 0.0001$) between both assays (**Supplementary Fig 9b**).

Statistical data analysis

Prevalence of SARS-CoV-2 antibodies or SARS-CoV-2 infection confirmed by rRT-PCR, and cumulative prevalence of past or current infection (positive SARS-CoV-2 rRT-PCR and/or antibody seropositivity at any time point) were calculated as proportions with 95% CI. We tested the association between variables with the Chi-square or Fisher's exact test for categorical variables, and with the Wilcoxon Sum Rank test for continuous variables. Paired Samples Wilcoxon Test was used for paired continuous data. We assessed the relationships between continuous variables using linear regression models and Spearman's rank correlation test. Locally estimated scatterplot smoothing (LOESS) was used to visualize trends in antibody levels over days PSO or post rRT-PCR diagnosis.

A Venn diagram was created to illustrate the overlap between anti-N full-length protein, anti-N C-term, anti-RBD, anti-S, anti-S1, anti-S2 in the Sustainer/Increaser groups⁵³.

Univariable and multivariable linear regression models were run to assess factors associated with SARS-CoV-2 antibody levels and prevalence. The variables tested were the following: sex and age, presence of COVID19 symptoms (individual symptoms also included - fatigue, cough, dyspnea and other respiratory symptoms, anosmia or ageusia, sore throat, fever, rhinorrhea, headache, chills and digestive symptoms-), n° of people living in the household and n° of children, worked in a COVID19 ward, type of job (doctor, nurse, administrative), had daily contact with patients, smoking habits, chronic medication, presence of baseline illness, previous contact with a positive COVID19 case.

We additionally explored the association between the SARS-CoV-2 antibody levels and the percentage of neutralization of RBD at month 6 in a Principal Components Analysis (PCA) that included all isotype/antigen pairs. Before the PCA, we confirmed the adequacy of the analysis by testing the collinearity of the variables with the Kaiser-Meyer-Olkin analysis (>0.5) and the Bartlett's sphericity test ($p < 0.001$). The number of factors chosen was based on eigenvalues >1 that explained >75% of the total variance. To investigate the relationships between HCoV levels and a subset of variables with clinical outcomes and SARS-CoV-2 antibody levels, we built multivariable logistic and linear models, respectively, for those participants for whom we had a sample prior to seroconversion.

A P-value of ≤ 0.05 was considered statistically significant and 95% and CIs were calculated for all estimates. We performed the statistical analysis in R version 4.0.3 (packages tidyverse and corrplot).

Data availability

Anonymized data used for this analysis is available and made public under the title of this publication at <http://diposit.ub.edu/dspace/handle/XXXXX>.

Code availability

Code used in the analysis is available at <http://diposit.ub.edu/dspace/handle/XXXX>.

References

1. WHO Coronavirus Disease (COVID-19) Dashboard. World Health Organization. Available at: <https://covid19.who.int/> (2021).
2. Dan, J. M. et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science* **371** (2021). doi:10.1126/science.abf4063
3. Graham, N. R. et al. Kinetics and Isotype Assessment of Antibodies Targeting the Spike Protein Receptor Binding Domain of SARS-CoV-2 In COVID-19 Patients as a function of Age and Biological Sex. Preprint at 10.1101/2020.07.15.20154443 (2020).
4. Moncunill, G. et al. SARS-CoV-2 Seroprevalence and Antibody Kinetics Among Health Care Workers in a Spanish Hospital After 3 Months of Follow-up. *The Journal of Infectious Diseases* **223** (2020).
5. Padoan, A. et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study. *Clinica Chimica Acta* **507** (2020).
6. Seow, J. et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. Preprint at: 10.1101/2020.07.09.20148429 (2020).
7. Tan, Y. et al. Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection. *Frontiers of Medicine* **14** (2020).
8. Iyer, A. S. et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. *Science Immunology* **5** (2020).
9. Figueiredo-Campos, P. et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. *European Journal of Immunology* **50**, 2025–2040 (2020).
10. Gaebler, C. et al. Evolution of Antibody Immunity to SARS-CoV-2. *Nature* (2021). doi:10.1101/2020.11.03.367391

11. Isho, B. et al. Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. *Science Immunology* **5**, 1-21 (2020). doi: 10.1126/sciimmunol.abe5511
12. Hartog, G. D. et al. SARS-CoV-2-specific antibody detection for sero-epidemiology: a multiplex analysis approach accounting for accurate seroprevalence. *The Journal of Infectious Diseases* **222**, 1452–1461 (2020). doi:10.1101/2020.06.18.20133660
13. Orth-Höller, et al. Kinetics of SARS-CoV-2 specific antibodies (IgM, IgA, IgG) in non-hospitalized patients four months following infection. *Journal of Infection* (2020). doi:10.1016/j.jinf.2020.09.015
14. Pradenas E. et al. Stable neutralizing antibody levels six months after mild and severe COVID-19 episode. *Med* **3**, 313-320 (2021)
15. Ripperger, T. J. et al. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. *Immunity* **53** (2020).
16. Whitcombe, A. L. et al. Comprehensive analysis of SARS-CoV-2 antibody dynamics in New Zealand. (2020). Preprint at 10.1101/2020.12.10.20246751
17. Chen, Y. et al. Quick COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production. *Cell* **183**, (2020).
18. Havervall, S. et al. SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection. (2021). Preprint at 10.1101/2021.01.03.21249162
19. Ibarrondo, F. J. et al. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19. *New England Journal of Medicine* **383**, 1085–1087 (2020).
20. L’Huillier, A. G. et al. Antibody persistence in the first six months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study. *Clinical Microbiology and Infection* (2021). doi:10.1016/j.cmi.2021.01.005
21. Wagner, A. et al. A longitudinal seroprevalence study in a large cohort of working adults reveals that neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six

- months independent of the severity of symptoms. (2020). Preprint at
10.1101/2020.12.22.20248604
22. Premkumar, L. et al. The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A
Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and
Animal Coronavirus Antibodies. (2020). Preprint at 10.1101/2020.05.06.20093377
23. Wajnberg, A. et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for
months. *Science* **370**, 1227–1230 (2020).
24. Garcia-Beltran WF., et al. COVID-19-neutralizing antibodies predict disease severity and
survival. *Cell* **184**, 476-488 (2021). <https://doi.org/10.1016/j.cell.2020.12.015>
25. Guthmiller, JJ. et al. SARS-CoV-2 Infection Severity Is Linked to Superior Humoral
Immunity against the Spike. *MBio* **12** (2021). doi: 10.1128/mBio.02940-20
26. Legros V., et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high
correlation between neutralizing antibodies and COVID-19 severity. *Cell Mol Immunol*
18, 318–27 (2021). <https://doi.org/10.1038/s41423-020-00588-2>
27. Takeshita, M. et al. Incomplete humoral response including neutralizing antibodies in
asymptomatic to mild COVID-19 patients in Japan. *Virology* **555**, 35–43 (2021).
28. Ma, Z., Li, P., Ji, Y., Ikram, A. & Pan, Q. Cross-reactivity towards SARS-CoV-2: the
potential role of low-pathogenic human coronaviruses. *The Lancet Microbe* **1**, (2020).
29. Arthur, W.E.E., et al. Seasonal coronaviruses protective immunity is short-lasting. *Nature*
Medicine **26**, 1691-1693 (2020).
30. Grifoni A., et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans
with COVID-19 Disease and Unexposed Individuals. *Cell* **181**, 1489-1501 (2020). doi:
10.1016/j.cell.2020.05.015.
31. Westerhuis BM., et al. Homologous and heterologous antibodies to coronavirus 229E,
NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-
sectional serosurvey in a large tertiary hospital in The Netherlands (2020). Preprint at
10.1101/2020.08.21.20177857

32. Aydililo, T. et al. Antibody Immunological Imprinting on COVID-19 Patients. (2020).
Preprint at 10.1101/2020.10.14.20212662
33. Assis, R. et al. Analysis of Serologic Cross-Reactivity Between Common Human
Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen Microarray. *Nature
Communications* **12**, (2020). doi:10.1101/2020.03.24.006544
34. Ng, K. W. et al. Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans.
Science **370** (2020). doi:10.1101/2020.05.14.095414
35. Becker, M. et al. Exploring beyond clinical routine SARS-CoV-2 serology using MultiCov-
Ab to evaluate endemic coronavirus cross-reactivity. *Nature Communications* **12**, 1152
(2021).
36. Dobaño, C. et al. Immunogenicity and crossreactivity of antibodies to SARS-CoV-2
nucleocapsid protein. *Translational Research* (2021). doi: 10.1016/j.trsl.2021.02.006
37. Anderson, E. M. et al. Seasonal human coronavirus antibodies are boosted upon SARS-
CoV-2 infection but not associated with protection. *Cell* (2020).
doi:10.1101/2020.11.06.20227215
38. Gombar, S. et al. SARS-CoV-2 infection and COVID-19 severity in individuals with prior
seasonal coronavirus infection. *Diagnostic Microbiology and Infectious Disease* (2020).
doi:10.1101/2020.12.04.20243741
39. Sagar, M. et al. Recent endemic coronavirus infection is associated with less-severe
COVID-19. *Journal of Clinical Investigation* **131**, (2021).
40. Arvin, A. M. et al. A perspective on potential antibody-dependent enhancement of SARS-
CoV-2. *Nature* **584**, 353–363 (2020).
41. Lee, W. S., Wheatley, A. K., Kent, S. J. & Dekosky, B. J. Antibody-dependent
enhancement and SARS-CoV-2 vaccines and therapies. *Nature Microbiology* **5**, 1185–
1191 (2020).
42. Garcia-Basteiro, A. L. et al. Seroprevalence of antibodies against SARS-CoV-2 among
health care workers in a large Spanish reference hospital. *Nature Communications* **11**,
(2020).

43. Barallat J., et al. Seroprevalence of SARS-CoV-2 IgG specific antibodies among healthcare workers in the Northern Metropolitan Area of Barcelona, Spain, after the first pandemic wave. *PLoS One* **15**, (2020). Doi: 10.1371/journal.pone.0244348
44. Fernandez, J. G. et al. Impact of SARS-CoV-2 pandemic among health care workers in a secondary teaching hospital in Spain. *Plos One* **16**, (2021).
45. Varona JF., et al. Seroprevalence of SARS-CoV-2 antibodies in over 6000 healthcare workers in Spain. *Int J Epidemiol* (2021). doi:10.1093/ije/dyaa277
46. Dobaño, C. et al. Persistence and baseline determinants of seropositivity in health care workers up to nine months after COVID-19. Preprint at: 10.21203/rs.3.rs-142984/v1
47. Self WH., et al. Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network — 12 States, April–August 2020. *MMWR* **69**, 1762–1766 (2020). doi:http://dx.doi.org/10.15585/mmwr.mm6947a2external icon
48. Adaken C., et al. Ebola virus antibody decay–stimulation in a high proportion of survivors. *Nature* (2021). doi: 10.1038/s41586-020-03146-y
49. Amanat F., et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med* **26**, 1033–1036 (2020). <https://doi.org/10.1038/s41591-020-0913-5>
50. Meyer B, Chiaravalli J, Brownridge P, Bryne DP, Daly LA, Agou F, et al. Characterisation of protease activity during SARS-CoV-2 infection identifies novel viral cleavage sites and cellular targets for drug repurposing (2020). Preprint from: <https://doi.org/10.1101/2020.09.16.297945>
51. Dobaño, C. et al. Highly sensitive and specific multiplex antibody assays to quantify immunoglobulins M, A and G against SARS-CoV-2 antigens. (2020). Preprint at 10.1101/2020.06.11.147363
52. Trinité, B., et al. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. *Sci Rep* **11**, 2608 (2021).

53. Heberle, H., Meirelles, G. V., Silva, F. R. D., Telles, G. P. & Minghim, R.
InteractiVenn: a web-based tool for the analysis of sets through Venn diagrams. *BMC Bioinformatics* **16**, (2015).

Author Contributions

A.A., A.L.G.B., P.E., G.M., A.M., C.D. designed the study. A.C., M.L., N.O., M.R., N.R., S.W. recruited participants, collected data and obtained samples at the clinic. A.J., M.V., R.A., R.R., D.B., R.A.M., L.P., S.A., C.J. processed the samples, developed and performed the serological assays and analysis. A.A., P.E., and P.H.L., performed the flow cytometry neutralization assay and E.P, B.T and J.B the pseudovirus-based neutralization assay. R.A, R.S., S.B., A.V., A.L., A.T., P.V., M.T. contributed to design and the critical interpretation of the results. J.C., L.I., N.R.M, C.C., P.Se., D.P., and P.Sa., produced the antigens. N.O., M.R., analyzed the data and R.S. gave support to data analysis. S.M. managed the clinical data. N.O., M.R., G.M., C.D. wrote the first draft of the paper. All authors approved the final version as submitted to the journal.

Acknowledgements

We thank the participation of health care workers who are committed with this study as well as with their professional activity that has a positive impact in the society, even more relevant during the pandemic. We are grateful to Eugénia Chóliz, Pau Cisteró, Antía Figueroa-Romero, Silvia Folchs, Jochen Hecht, Mikel J. Martínez, Núria Pey, Patricia Sotomayor and Sara Torres who participated in the field and/or laboratory work during previous visits. We also thank Cristina Castellana and the administrative department in ISGlobal, Sergi Sanz and Sergio Olmos for statistical advice, Jordi Rello for scientific advice, and the nurses from Occupational Health and Preventive Medicine departments (HCB).

Funding

This work was supported by Institut de Salut Global de Barcelona (ISGlobal) internal funds; in-kind contributions of Hospital Clínic de Barcelona, and European Institute of Innovation and Technology (EIT) Health (grant number 20877), supported by the European Institute of Innovation and Technology, a body of the European Union receiving support from the H2020 Research and Innovation Programme; by the Fundació Provada Daniel Bravo Andreu through the high-throughput equipment they provided; Ministerio de Ciencia e Innovación through the Centro de Excelencia Severo Ochoa 2019–2023 program (grant number CEX2018-000806-S); and the Catalan Government through the Centres de Recerca de Catalunya program (for P.S.: 2017-SGR-3380 and MINECO RTI2018-093964-B-I00). . G. M. was supported by the Departament de Salut, Generalitat de Catalunya (grant number SLT006/17/00109). L. I. work was supported by PID2019-110810RB-I00 grant from the Spanish Ministry of Science & Innovation.

Work at IrsiCaixa was partially funded by Grifols, the Departament de Salut of the Generalitat de Catalunya (grant SLD016 to JB), the Spanish Health Institute Carlos III (Grant PI17/01518. PI20/00093 to JB), CERCA Programme/Generalitat de Catalunya 2017 SGR 252, and the crowdfunding initiatives #joemcorono, BonPreu/Esclat and Correos. EP was supported by a doctoral grant from National Agency for Research and Development of Chile (ANID): 72180406.

The funders had no role in study design, data collection and analysis, the decision to publish, or the preparation of the manuscript.

Competing interests

The authors declare no competing interests.

Figures

Figure 1. Kinetics of SARS-CoV-2 antibody levels since onset of symptoms. Levels (median fluorescence intensity, MFI) of IgA, IgG and IgM against each antigen (Nucleocapsid full length protein (N), and its C-terminal domain, the Receptor Binding Domain (RBD), full S protein and its subregions S1 and S2) measured in 357 samples from 76 symptomatic participants collected in up to four time points per participant (paired samples joined by lines). The black solid line represents the fitted curve calculated using the LOESS (locally estimated scatterplot smoothing) method. Shaded areas represent 95% confidence intervals. Dashed line represents the positivity threshold. Participants were grouped based on their antibody levels at M6 compared to the previous visit, individuals were labelled for each isotype-antigen pair as “Decayers” (pink) when the ratio of antibody levels between both visits was <1 and as “Sustainers/Increarer” (light blue) when the ratio was ≥ 1 and grey when the classification was not applicable.

Figure 2. Longitudinal antibody neutralizing capacity. Antibody neutralizing capacity, as a percentage of ACE2 binding inhibition in plasma samples from 64 symptomatic participants collected in three serial visits (M0, M1 and M6) represented as days after symptom onset. Paired samples are joined by grey lines. The black solid line represents the fitted curve calculated using the LOESS (locally estimated scatterplot smoothing) method. Shaded areas represent 95% confidence intervals.

Figure 3. Correlations between antibody levels and RBD-ACE2 neutralization capacity.

Spearman's rank correlation test between levels (median fluorescence intensity, MFI) of IgA, IgG and IgM against each antigen (Nucleocapsid full length protein (N), and its C-terminal domain, the Receptor Binding Domain (RBD), full S protein and its subregions S1 and S2) at **a**) baseline visit (M0) and **b**) M6 visit; and plasma neutralization capacity (as a percentage of RBD-ACE2 binding inhibition). P-values and r_s correlation coefficients are color-coded for each antigen/isotype pair. Colored lines represent the fitted curve calculated using the linear model method. Shaded areas represent 95% confidence intervals.

Figure 4. The influence of anti-HCoV antibody levels on the antibody response to SARS-CoV-2. **a)** Differences in baseline levels (median fluorescence intensity, MFI) of IgG against HCoV N protein between participants who were seronegative during the entire study (COVID-19 Ab-) and participants who seroconverted (COVID-19 Ab+). **b)** Differences in IgA, IgG and IgM levels prior to infection against N of the four HCoVs between symptomatic and asymptomatic participants who seroconverted during the study. **c)** Differences in fold-increase of IgG levels against N of the four HCoVs after SARS-CoV-2 seroconversion in symptomatic vs asymptomatic COVID-19 cases. **d)** Differences in anti-HCoV N IgG levels at seroconversion visit between symptomatic and asymptomatic SARS-CoV-2 seropositive participants. **e)** Differences in anti-SARS-CoV-2 N IgG, IgA and IgM levels in asymptomatic versus symptomatic participants at seroconversion visit.

Extended data figures

		Total
Sex ^a	Male	161 (28%)
	Female	417 (72%)
Professional Category ^a	Nurse / Auxiliary / Stretcher-bearer	288 (50%)
	Physician	147 (25%)
	Lab technicians	45 (8%)
	Admin officers Other ⁶	98 (17%)
Age ^c		42.1 (11.6)
Daily contact with patients ^a	No	123 (21%)
	Yes	455 (79%)
Working in a COVID19 unit ^a	No	315 (54%)
	Yes	263 (46%)
Close contact with COVID19 confirmed or suspected case ^a	No	137 (24%)
	Yes	441 (76%)
Previously diagnosed of COVID19 by RT-qPCR ^a	No	539 (93%)
	Yes	39 (7%)
Comorbidities ^a	No	517 (89%)
	Yes	61 (11%)
Household size ^c		2.8 (1.2)
Received Flu vaccine (2019-2020 season) ^a	No	339 (59%)
	Yes	239 (41%)
Reporting COVID-19 compatible symptoms within previous month ^a	No	368 (64%)
	Yes	210 (36%)

^a n (Column percentage)

^b Includes, cleaning, kitchen and maintenance staff

^c Arithmetic Mean (SD) [n]

^d Comorbidities include: heart and liver disease, diabetes, chronic respiratory and renal disease, cancers and autoimmune and other immunological disorders.

Supplementary Table 1. Baseline characteristics of study participants.

Supplementary Figure 1. Kinetics of SARS-CoV-2 antibody levels since day of first positive rRT-PCR test. Levels (median fluorescence intensity, MFI) of IgA, IgG and IgM against each antigen (Nucleocapsid full length protein (N), and its C-terminal domain, the Receptor Binding Domain (RBD), full S protein and its subregions S1 and S2). Data are shown only for the 67 participants who had a positive rRT-PCR. Up to four time points are shown per participant (paired samples joined by lines). The black solid line represents the fitted curve calculated using the LOESS (locally estimated scatterplot smoothing) method. Shaded areas represent 95% confidence intervals.

	visit	All isotypes(%) [95% CI]	IgA (%) [95% CI]	IgG (%) [95% CI]	IgM (%) [95% CI]
Seroprevalence*	M0	78/578 (13.5%) [10.8- 16.6%]	60/578 (10.4%) [8.0-13.2%]	42/578 (7.6%) [5.3-9.7%]	53/578 (9.2%) [6.9-11.8%]
	M1	86/566 (15.6%) [12.3-18.4%]	61/566 (10.8%) [8.3-13.6%]	59/566 (10.8%) [8.0-13.2%]	54/566 (9.6%) [7.2-12.3%]
	M6	83/507 (16.4%) [13.3-19.9%]	58/507 (11.4%) [8.8-14.5%]	58/507 (11.4%) [8.8-14.5%]	35/507 (6.9%) [4.9-9.5%]
Seroconversion*	M1	23/500 (4.6%)	20/500 (4.0%)	21/500 (4.2%)	19/500 (3.8%)
	M6	13/478 (2.7%)	10/478 (2.1%)	12/478 (2.5%)	11/478 (2.3%)
Seroreversion	M1	7/78 (9.0%)	18/60 (30.0%)	2/44 (4.5%)	13/53 (24.5%)
	M3	6/88 (6.8%)	14/61 (23.0%)	6/61 (9.8%)	16/54 (29.6%)
	M6	0/49 (0.0%)	1/30 (3.3%)	1/44 (2.3%)	1/12 (8.3%)

Supplementary Table 2. Seroprevalence, seroconversion and seroreversion rates for each visit.

*Only participants with previous evidence of SARS-CoV-2 infection were invited to visit M3, thus, no seroprevalence or seroconversion data are presented for this visit.

720

	OR (95% CI)	
	Univariable Logistic Regression	p value
Age	1.00 (0.98-1.02)	0.9365
Sex		
Females	1.33 (0.83-2.20)	0.241
Males	1.0 (Ref)	
Job function		
Nurses and auxiliary health professionals ^a	1.0 (Ref)	
Laboratory and other technicians	0.92 (0.40-1.94)	0.8314
Physicians and psychologists	0.49 (0.27-0.85)	0.0138 *
Others ^b	0.88 (0.49-1.53)	0.6618
Involved in clinical care		
Yes	1.17 (0.70-2.01)	0.56
No	1.0 (Ref)	
Worked in a COVID ward		
Yes	0.90 (0.59-1.39)	0.634
No	1.0 (Ref)	
Baseline illness ^c		
Yes	0.79 (0.45-1.33)	0.385
No	1.0 (Ref)	
Chronic medication		
Yes	0.69 (0.39-1.18)	0.19
No	1.0 (Ref)	
Symptomatic		
Yes	153.2 (67.3-416.3)	<2e-16 ***
No	1.0 (Ref)	
N° children co-living	1.02 (0.78-1.30)	0.901
N° people household	1.04 (0.87-1.24)	0.679
Smoker		
Yes	0.78 (0.45-1.31)	0.373
No	1.0 (Ref)	

721 **Supplementary Table 3.** Univariable analysis of factors associated with having detectable
722 SARS-CoV-2 antibodies at M6 (IgM and/or IgG and/or IgA against each antigen
723 (Nucleocapsid (N), and its C-terminal domain, the Receptor Binding Domain (RBD), full S
724 protein and its subregions S1 and S2). All factors explored are included in the table.

725 * p-value <0.05

726 *** p-value < 0.001

727 ^a Includes stretcher-bearer.

728 ^b Includes, cleaning, kitchen and maintenance staff

729 ^c Comorbidities include heart and liver disease, diabetes, chronic respiratory and renal
730 disease, cancers and autoimmune, and other immunological disorders.

731

732

Dependent variable:	
	Beta (SE)
Component 1 ^a	3.893*** (0.482)
Component 2	0.932 (0.649)
Component 3	-0.923 (0.811)
Component 4	-0.585 (0.918)
Component 5 ^b	3.579*** (1.108)
Constant	34.488*** (1.151)
Observations	56
R ²	0.614
Adjusted R ²	0.575
Residual Std. Error	8.615 (df = 50)
F Statistic	15.903*** (df = 5; 50)
<i>Note:</i> *p<0.1; **p<0.05; ***p<0.01	

733 ^a Mostly contributing to the Component 1: S1 IgG (0.374) / S IgG (0.381)

734 ^b Mostly contributing to the Component 5: N C terminal IgG (-0.656) / S2 IgM (0.355)

735

736

737 **Supplementary Table 4.** Principal Components Regression. SE: Standard Error.

738

Supplementary Figure 3. Comparisons of serological and clinical characteristics between sustainers/increasers and decayers. **a)** Differences in antibody levels at seroconversion between sustainers/increasers and decayers (median fluorescence intensity, MFI) of IgA, IgG and IgM against each antigen (Nucleocapsid (N), and its C-terminal domain, the Receptor Binding Domain (RBD), full S protein and its subregions S1 and S2)). **b)** Differences in antibody increase index (represented in log scale) between seropositive participants who reported symptoms and those who did not in month 6 (M6) after recovering from a previous SARS-CoV-2 infection. **c)** Differences in antibody increase index (represented in log scale) between seropositive symptomatic participants who reported less than 10 days of symptom duration and those who reported more than 10 days.

Supplementary Figure 4. Principal Components Analysis (PCA) Biplot. Vectors represent all antigen/isotype pairs and their contribution to the variance in the antibody neutralization percentage represented in the two main dimensions axis. Observations are plotted according to their neutralization percentage at fourth visit (M6).

Supplementary Figure 5. a) Sample collection timeline. **b)** Correlations between antibody increase index and neutralization capacity. Spearman's rank correlation test between antibody increase index (MFI increase between M6 and previous visit) of IgA, IgG and IgM against each study antigen (Nucleocapsid full length protein (N), and its C-terminal domain, the Receptor Binding Domain (RBD), full S protein and its subregions S1 and S2), and the plasma neutralization capacity at M0 (as a percentage of RBD-ACE2 binding inhibition). P-values and r_s correlation coefficients are color-coded for each antigen/isotype pair. Colored lines represent the fitted curve calculated using the linear model method. Shaded areas represent 95% confidence intervals.

Supplementary Figure 6. Correlation plot with hierarchical clustering showing the correlations between IgG, IgM and IgA levels against Nucleocapsid (N) protein from the four seasonal human coronaviruses (HCoV) and SARS-CoV-2 in 101 pre-pandemic samples. Significance level in the correlations is represented by * (p < 0.05), ** (p < 0.01), *** (p < 0.001). Bold letters highlight SARS-CoV-2 coronavirus for visualization purposes.

Supplementary Figure 7. Boxplots comparing the levels (median fluorescence intensity, MFI) of IgA, IgG and IgM against the Nucleocapsid (N) protein of the four seasonal human coronaviruses (HCoV) before and after SARS-CoV-2 seroconversion.

Supplementary Figure 8. Linear regression models showing the relation between antibody levels against the four HCoV N proteins (three isotypes added) and the anti-SARS-CoV-2 N antibody ratio of seroconversion (seroconversion levels/baseline levels) for all three isotypes. P-values and r_s correlation coefficients are given for each isotype. Black lines represent the fitted curve calculated using the linear model method. Shaded areas represent 95% confidence intervals.

Supplementary Figure 9. a) Antibody neutralization capacity is compared between negative controls, positive controls and participants. b) Correlation between neutralization values as per the flow cytometry assay used for this work and values from a cross-validated pseudovirus neutralization assay (ID50 - half maximal dilutions concentrations).

Supplementary Information

Quantification of antibodies to SARS-CoV-2 by Luminex

The levels of IgG, IgM and IgA were assessed in single replicates by high-throughput multiplex quantitative suspension array technology (qSAT). The assay was performed in 6 plates of 384 wells with samples from the same individual in the same plate (samples from visit M0 to M6). The SARS-CoV-2 antigens included were the spike full protein (S) (aa 1-1213 expressed in Expi293 and His tag-purified), the S1 (aa 1-681, expressed in Expi293 and His tag-purified) and S2 (purchased from SinoBiologicals), the receptor binding domain (RBD) (fused with C-terminal 6xHis and StrepTag purification sequences and purified from supernatant of lentiviral-transduced CHO-S cells cultured under a fed-batch system), the nucleocapsid full protein (N) and the specific N C-terminal region, and the four HCoV N full length proteins (expressed in *E. coli* and His tag-purified). Assay performance was previously established as 100% specificity and 95.78% sensitivity for seropositivity 14 days after symptoms onset [1].

Coupling of proteins to microspheres

MagPlex® polystyrene 6.5 µm COOH-microspheres (Luminex Corp, Austin, TX, USA) were washed, sonicated and activated with Sulfo-NHS (*N*-hydroxysulfosuccinimide) and EDC (1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride) (Thermo Fisher Scientific Inc., Waltham USA). Next, microspheres were washed and resuspended in 50 mM MES pH 5.0 (MilliporeSigma, St. Louis, USA). The recombinant proteins were then incubated with the microspheres at the optimal concentrations (from 10 to 50 µg/mL) and left at 4°C on a shaker overnight. Coupled microspheres were resuspended in PBS with 1% BSA to covalently block the free carboxylic group (-COOH) absorbing most of the non-specific binding to secondary or tertiary antibodies during assay steps [2] and heterophilic antibody binding seen in previous systems [3]. Microspheres recovery were quantified on a Guava® easyCyte™ Flow Cytometer (Luminex Corporation, Austin, USA). Equal amounts of each antigen-coupled microspheres were multiplexed and stored at 2000 microspheres/µL at 4°C, protected from light.

qSAT assay

Antigen-coupled microspheres were added to a 384-well µClear® flat bottom plate (Greiner Bio-One, Frickenhausen, Germany) in multiplex (2000 microspheres per analyte per well) in a volume of 90 µL of Luminex Buffer (1% BSA, 0.05% Tween 20, 0.05% sodium azide in PBS) using 384 channels Integra Viaflo semi-automatic device (96/384, 384 channel pipette). Two hyperimmune pools (one for IgG and IgA, and another one for IgM) were used as positive controls in each plate assay for QA/QC purposes and were prepared at 2-fold, 8 serial dilutions from 1:12.5. Pre-pandemic samples were used as negative controls to estimate the cut off of seropositivity. Ten µL of each dilution of the positive control, negative controls and test samples (prediluted 1:50 in 96 round-bottom well plates), were added to a 384-well plate using Assist Plus Integra device with 12 channels Voyager pipette (final test sample dilution of 1:500). To quantify IgM responses, test samples and controls were pre-treated with anti-Human IgG (Gullsorb) at 1:10 dilution, to avoid IgG interferences. Technical blanks consisting of Luminex Buffer and microspheres without samples were added in 4

wells to detect and adjust for non-specific microsphere signals. Plates were incubated for 1 h at room temperature in agitation (Titramax 1000) at 900 rpm and protected from light. Then, the plates were washed three times with 200 μ L/well of PBS-T (0.05% Tween 20 in PBS), using BioTek 405 TS (384-well format). Twenty five μ L of goat anti-human IgG-phycoerythrin (PE) (GTIG-001, Moss Bio) diluted 1:400, goat anti-human IgA-PE (GTIA-001, Moss Bio) 1:200, or goat anti-human IgM-PE (GTIM-001, Moss Bio) 1:200 in Luminex buffer were added to each well and incubated for 30 min. Plates were washed and microspheres resuspended with 80 μ L of Luminex Buffer, covered with an adhesive film and sonicated 20 seconds on sonicator bath platform, before acquisition on the Flexmap 3D[®] reader. At least 50 microspheres per analyte per well were acquired, and median fluorescence intensity (MFI) was reported for each analyte.

Neutralizing antibodies

The stable cell line 300.19-ACE2 was obtained by transfecting 300.19 cells with a plasmid encoding human ACE2 cDNA (SinoBiological) with an Amaxa cell line Nucleofector kit V, followed by hygromycin selection and subsequent subcloning. RBD-mFc fusion protein, containing RBD fused to the Fc region of murine IgG1 was obtained by cloning RBD amplified from the pcDNA3-SARS-CoV-2-S-RBD-Fc (Addgene) into the PFUSE-mIgG1-Fc1 (InvivoGen). HEK-293T cells were transiently transfected with the RBD-mFc plasmid using polyethylenimine as previously described [4]. The supernatant containing the RBD-mFc protein was collected 7 days after transfection, and concentrated 4-fold using an Amicon Ultra-15 Centrifugal Filter Unit with an Ultracel-30 membrane (Millipore). A total of 1.2×10^3 300.19-ACE2 cells per well in a 96-well plate were incubated for 30 min at 4°C with 4 mg/mL of RBD-mFc fusion protein previously exposed to diluted plasma (1:50) for 30 min at 4°C. Samples were stained with anti-mouse IgG-PE (Jackson ImmunoResearch), washed, and analyzed by Flow cytometry using standard procedures. Samples were acquired with a FACSCanto II (BD Biosciences) and analyzed with FlowJo Xv10.0.7 (Tree Star, Inc) software [4]. Pseudovirus-based neutralization assay using HIV-based pseudovirus and ACE2 expressing 293T cells is described in Pradenas et al. [5]. This assay has been validated by direct comparison of IC₅₀ neutralization values obtained using pseudoviruses infecting ACE2 expressing 293 cells and replicative viruses infecting Vero cells in Trinité et al. [6].

Supplementary References

- [1] Dobaño, C. et al. Highly sensitive and specific multiplex antibody assays to quantify immunoglobulins M, A and G against SARS-CoV-2 antigens. (2020). Preprint at 10.1101/2020.06.11.147363
- [2] Waterboer T, Sehr P, Pawlita M. Suppression of non-specific binding in serological Luminex assays. *J Immunol Methods* **309**, 200–4 (2006)
- [3] Martins TB, Pasi BM, Litwin CM, Hill HR. Heterophile antibody interference in a multiplexed fluorescent microsphere immunoassay for quantitation of cytokines in human serum. *Clin Diagn Lab Immunol* **11**, 325-9 (2004)
- [4] Martínez-Vicente P, Farre D, Sánchez C, Alcamí A, Engel P, Angulo A. Subversion of

890 natural killer cell responses by a cytomegalovirus-encoded soluble CD48 decoy receptor.
 891 *PLoS Pathog* **15** (2019)
 892 [5] Pradenas E. et al. Stable neutralizing antibody levels six months after mild and severe
 893 COVID-19 episode. *Med* 3, 313-320 (2021)
 894 [6] Trinité, B., et al. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that
 895 correlates with disease severity. *Sci Rep* 11, 2608 (2021).
 896